|By PR Newswire||
|October 8, 2013 08:11 AM EDT|
NEW YORK, October 8, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Sotheby's (NYSE: BID), Outerwall Inc. (NASDAQ: OUTR), Team Health Holdings, Inc. (NYSE: TMH), Myriad Genetics Inc. (NASDAQ: MYGN), and ExamWorks Group, Inc. (NYSE: EXAM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Sotheby's Research Report
On September 23, 2013, Sotheby's announced that William S. Sheridan, Executive Vice President and Chief Financial Officer is leaving the Company after serving for 17 years, and will be replaced by Patrick S. McClymont, a partner and managing director at Goldman, Sachs & Co., with effect from October 7, 2013. The Company also informed that Mr. Sheridan will remain with Sotheby's through the end of 2013 to support the CFO transition. Mr. Sheridan commented, "I have had the privilege of working with a highly skilled, highly professional finance, investor relations and information technology team at Sotheby's that I invested in and helped build, and they deserve an enormous amount of credit for all that we accomplished. It has been a true pleasure to be part of Sotheby's and now I look forward to spending more time with my family and focusing on charitable work." The Full Research Report on Sotheby's - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/a614_BID]
Outerwall Inc. Research Report
On September 16, 2013, Outerwall, Inc. (Outerwall) announced financial guidance updates for Q3 2013 and full-year 2013. Outerwall stated that for Q3 2013, the Company anticipates consolidated revenue to be in the range of $569 and $589 million, compared to prior estimates of $604 to $630 million; and core diluted EPS between $0.82 and $0.94, compared to prior estimate range of $1.36 and $1.51. For full-year 2013, the Company anticipates consolidated revenue to be in the range of $2.27 billion and $2.34 billion, compared to prior estimates of $2.37 billion to $2.48 billion; core diluted EPS between $4.72 and $5.12, compared to prior estimates of $5.76 to $6.26. "Although both rentals and revenue for Redbox increased significantly in July and August over 2012 levels, they were not to our expectations. In addition, heightened promotional discount activity, which added new customers during the quarter, had an adverse impact on the expected average transaction size and we believe drove consumers toward more single night rentals," said J. Scott Di Valerio, CEO of Outerwall Inc. The Full Research Report on Outerwall Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b53c_OUTR]
Team Health Holdings, Inc. Research Report
On October 1, 2013, TeamHealth announced that Daniel Virnich, MD, MBA has been appointed as the Chief Medical Officer for TeamHealth Hospital Medicine (THHM) with effect from October 1, 2013. According to the Company, Dr. Virnich will be responsible for the clinical effectiveness of THHM programs and will play a major role in the organization's clinical integration efforts. "With diverse experience in both healthcare and business, Dr. Virnich offers the necessary knowledge and skills to provide leadership for our client hospitals, affiliated physicians, advanced practice clinicians and employees," said Jasen Gundersen, MD, MBA, CPE, SFHM, President of TeamHealth Hospital Medicine. "The combination of his clinical knowledge and healthcare administrative experience makes him well-suited to be chief medical officer for TeamHealth's hospital medicine division." The Company also informed that prior to this new role Dr. Virnich served as a regional medical director for THHM's west division. The Full Research Report on Team Health Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/f4f2_TMH]
Myriad Genetics Inc. Research Report
On October 1, 2013, Myriad Genetics Inc. (Myriad Genetics) announced that BioMarin Pharmaceutical Inc. will use the Company's BRACAnalysis test in connection with its pivotal Phase 3 clinical studies for BMN 673. According to the Company, BMN 673 is a novel, orally-active PARP inhibitor designed to induce synthetic lethality in BRCA-deficient cells. Myriad Genetic informed that as required by the U.S. Food and Drug Administration (FDA), the Company also submitted an Investigational Device Exemption (IDE) to the FDA that will allow for BRACAnalysis testing to be used as a companion diagnostic to stratify patients in the BMN 673 clinical program. Mark C. Capone, President of Myriad Genetics Laboratories said, "Companion diagnostics are a major focus of our business and are increasingly being integrated into drug development programs, BRACAnalysis has shown promise as a companion diagnostic, and we are actively collaborating with BioMarin to identify responders and non-responders to therapy with BioMarin's novel PARP inhibitor." The Full Research Report on Myriad Genetics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4acb_MYGN]
ExamWorks Group, Inc. Research Report
On October 1, 2013, ExamWorks Group, Inc. (ExamWorks) announced its upcoming participation at the Credit Suisse Annual Health Conference in Scottsdale, Arizona. The Company stated that the presentation will be held on November 13, 2013 at The Phoenician in Scottsdale, Arizona. ExamWorks informed that Richard E. Perlman, Executive Chairman and James K. Price, CEO of ExamWorks Group, Inc. will lead the presentation. The Full Research Report on ExamWorks Group, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5214_EXAM]
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner